Atlas›Domain XII · Complementary, energy & biofield›Guide 156
Guide XII-156

Antineoplastons (Burzynski)

Stanislaw R. Burzynski1976United States
A 33 · L 55 · M 1211 interventions in the Trinity explorer
Client cardCompare
[source: …] where a claim comes from[uncertain] not confirmed in a primary source[synthesis] the writer's reconstruction

Version followed: antineoplaston therapy as offered by Stanislaw R. Burzynski, MD, PhD, through the Burzynski Clinic and Burzynski Research Institute (BRI), Houston, Texas, from 1977 onward, as described by the US National Cancer Institute (NCI) PDQ summary, Texas court and Attorney General records, FDA enforcement reporting (2012–2013) and Texas Medical Board actions (1994, 2017). This is a historical account for recognition and harm prevention. It is not a treatment guide, and antineoplastons are not presented here as a treatment for cancer or any other disease.

1. What it was

Who, where, when. Antineoplastons are a group of compounds that Burzynski began developing while in medical school in Poland in the 1960s; he left a laboratory post at Baylor College of Medicine in 1977, opened a Houston laboratory and began private practice using them [source: Texas State Board of Medical Examiners v. Burzynski, 1996]. NCI dates the first proposal of antineoplastons as a possible cancer treatment to 1976 [source: NCI PDQ].

Stated rationale (as the developer framed it). Burzynski proposed, drawing on cybernetic information theory, that the body has a natural biochemical "surveillance" system of peptides that signal cells to differentiate normally, that people with cancer lack these peptides, and that replacing them would restore normal differentiation [source: NCI PDQ]. The clinic's website described the treatment as based on "the natural biochemical defense system of our body" [source: BMJ 2011;343:d7865]. The compounds were first isolated from human blood, then from urine (cheaper and easier to obtain), and since 1980 have been synthesised from commercial chemicals [source: NCI PDQ]. Named preparations include A10, AS2-1 (a mixture of phenylacetic acid and phenylacetylglutamine), AS2-5 (phenylacetylglutamine), A2, A3, A5 and others. Proposed mechanisms (DNA intercalation, interference with glutamine transport, inhibition of DNA methylation) have not been conclusively shown [source: NCI PDQ].

Regulatory and evidence status (one line each). Regulatory: "not approved by the U.S. Food and Drug Administration for the prevention or treatment of any disease" [source: NCI PDQ]. Evidence: no randomised controlled trial showing effectiveness has been published in the peer-reviewed literature, and no phase III trial has been conducted; most human reports are case reports and phase I or toxicity studies by the developer, often confounded by prior or concurrent therapy [source: NCI PDQ]. NCI no longer updates its summary and keeps it for reference only [source: NCI PDQ].

How it was sold to patients and referrers.

  • Claims of response. A clinic brochure examined by a Texas appeals court stated that "The majority of cancer patients treated in [the] Institute showed positive response to treatment," claimed long-term remissions, and included sections on costs, insurance, appointments and travel; the court treated it as commercial speech about an illegal activity [source: Texas State Board of Medical Examiners v. Burzynski, 1996].
  • Television, film and celebrity. Burzynski first gained wide attention through a 1988 television segment featuring four of his patients; supporters later included a television doctor and a filmmaker who made two documentaries about him; reporting describes him as having gained a devoted following that drew on conspiracy theories and anti-pharmaceutical-industry sentiment [source: Fox News, 2013]. Physician critics describe the documentaries as one-sided promotional films [source: Science-Based Medicine, 2013].
  • "Pioneering" and "not available here." Families outside the US raised large sums to travel to Houston; one UK family's estimated cost was £200,000, with the treatment described in the press as "pioneering" and "not available in this country, it is new" [source: BMJ 2011;343:d7865].
  • "Clinical trials" as the access route. After state litigation, a 1998 final judgment restricted Burzynski to giving antineoplastons only to patients in FDA-approved clinical trials (unless the FDA approved the drug) and required his advertising to state that safety and effectiveness had not been established [source: Texas Attorney General news release, 1998]. Treatment was therefore offered as enrolment in a "clinical trial". By 2013, reporting citing the US National Institutes of Health stated he had completed one of more than 60 studies he had started, most listed as "unknown" or "withdrawn", with no randomised controlled trial reported [source: Fox News, 2013].
  • Personalised or "gene-targeted" framing. Burzynski also presented himself as a pioneer of genomic, personalised cancer therapy; critics state his publication record does not support this [source: Science-Based Medicine, 2013].
  • Pressure on critics. In 2011 the clinic threatened UK bloggers with legal action over their criticism of its treatments [source: BMJ 2011;343:d7865].

Legal and regulatory timeline (as sources report it).

  • 1983–1984: a federal permanent injunction barred interstate shipment of antineoplastons without FDA approval; it did not address distribution within Texas [source: Texas State Board of Medical Examiners v. Burzynski, 1996; Texas Attorney General, 1998].
  • 1986: Burzynski gave the Texas board partial records for about 60 patients; two reviewing oncologists could not conclude the treatment had helped them [source: Texas State Board of Medical Examiners v. Burzynski, 1996].
  • 1991–1995: NCI-funded phase II trials of A10 and AS2-1 enrolled only nine patients and closed early in August 1995 after disagreements over changes to accrual and dosing [source: NCI PDQ].
  • 31 August 1994: the Texas State Board of Medical Examiners suspended his licence, stayed the suspension and placed him on ten years' probation, on counts including unlawful use of antineoplastons, false advertising and improper fee collection; in 1996 the Texas Court of Appeals upheld the board, holding that Texas law did not authorise him to distribute drugs not approved by the FDA [source: Texas State Board of Medical Examiners v. Burzynski, 1996].
  • 1992–1998: Texas sued Burzynski and BRI over treating patients with an unapproved drug and advertising it as effective against cancer; the 1998 final judgment imposed the trial-only and advertising restrictions above and $50,000 in costs [source: Texas Attorney General, 1998].
  • 2012: after a child's death, the FDA placed a partial clinical hold (no new patients enrolled; current patients could continue) on trials involving children; the hold was later extended to adults [source: Science-Based Medicine, 2013, reporting USA Today].
  • 2013: FDA inspected the antineoplaston studies from 7 January to 15 March 2013 and on 15 March issued Burzynski, as clinical investigator, a Form 483 of inspectional observations (stated to be observations, not a final agency determination) [source: FDA Form 483, 2013]. Warning letters dated 3 December 2013 followed to BRI as sponsor and to Burzynski as clinical investigator [source: RegDataLab entries for both letters; Respectful Insolence, 2013, reproducing the letters] [uncertain: letter text known from secondary copies].
  • 2014–2017: the Texas Medical Board brought charges including misleading terminally ill patients; the State Office of Administrative Hearings found, among other violations, that in at least one case Burzynski did not follow the protocol the patient had consented to and that a clinician misrepresented herself as authorised to practise medicine, while finding insufficient evidence of deceptive advertising or of harm from these violations [source: STAT, 2017]. In March 2017 the board placed him on five years' probation with $40,000 in fines and $20,000 restitution to a former patient, more lenient than its staff had proposed (staff had proposed revocation, then at least four years' probation and $380,000 in fines) [source: FOX 7 Austin, 2017; STAT, 2017].
  • Current operating status of the clinic: not established by the sources cited here [uncertain].

2. What was actually done

The sequence below is assembled from regulatory, court and press sources; individual patients' courses varied, and details that sources did not report are marked.

  1. Who came. Mostly people with advanced or recurrent cancers, prominently brain tumours, including children, many of whom had already received surgery, radiotherapy or chemotherapy [source: NCI PDQ; Fox News, 2013; BMJ 2011]. Families typically found the clinic through media coverage, documentaries, testimonials and word of mouth, often after being told by their own oncologists that cure was unlikely [source: Fox News, 2013; synthesis].
  2. Selection and "enrolment". Patients were enrolled in one of the clinic's FDA-registered studies or treated under expanded (individual) access, because the 1998 judgment allowed antineoplastons only within FDA-approved trials [source: Texas Attorney General, 1998; Respectful Insolence, 2013]. FDA inspectors found the clinic repeatedly failed to ensure patients had a required waiting period after earlier treatment before starting the new one [source: FDA Form 483, 2013 (eligibility observations); Science-Based Medicine, 2013].
  3. Money and consent. Payment was commonly demanded up front: reporting describes up to $20,000 to start and $7,500 per month thereafter, not covered by most insurance [source: Fox News, 2013], and one family was asked for $25,000 up front by cash or cheque [source: Science-Based Medicine, 2013, reporting USA Today]. Overseas families raised sums such as £200,000 through public appeals [source: BMJ 2011]. FDA found the consent form omitted a statement of additional costs and that in some cases the billing agreement was signed days to weeks after consent [source: FDA Form 483, 2013]. A consent form listed the risk of hypernatraemia (dangerously high blood sodium) at 21% [source: Science-Based Medicine, 2013].
  4. Setting and administration (qualitative only). Treatment was organised from the Houston clinic. Historically antineoplastons were given by many routes (intravenous, intramuscular, rectal, topical, into the chest cavity, bladder instillation); in later practice they were given orally or by injection, with clinical studies using intravenous lines including subclavian (central) venous catheters [source: NCI PDQ]. Families continuing treatment at home, including carrying portable infusion equipment, is widely described [uncertain].
  5. Combined drugs. Published reports describe responses that were uncontrolled and often combined with chemotherapy or radiation [source: NCI PDQ]. Patients classified as responding were in some cases receiving corticosteroids (dexamethasone) at levels FDA described as far above physiological replacement, which FDA said undermined the response classifications [source: Respectful Insolence, 2013, reproducing FDA letters]. A "personalised" or "gene-targeted" approach was also marketed [source: Science-Based Medicine, 2013].
  6. How "progress" was judged. FDA found the clinic inflated success rates, classified patients as complete or stable responses while on high-dose steroids, kept case report forms that differed between what was sent to FDA and what inspectors found on site, and failed to keep accurate case histories in expanded-access cases; FDA's inspection also found that baseline and on-treatment scan measurement worksheets had been destroyed and that many response assignments did not meet protocol criteria [source: FDA Form 483, 2013; Respectful Insolence, 2013; Fox News, 2013]. Testimonials from patients who believed themselves cured were central to promotion [source: Science-Based Medicine, 2013].
  7. Adverse events and non-response. FDA said Burzynski failed to report side effects and to prevent patients from repeatedly overdosing [source: FDA Form 483, 2013; Respectful Insolence, 2013, citing USA Today]. When a child died with an extremely high recorded sodium level, clinic staff attributed the reading to a contaminated laboratory sample [source: Science-Based Medicine, 2013]. The State Office of Administrative Hearings found that in at least one case the treatment given departed from the protocol the patient had consented to [source: STAT, 2017]. How refusal or withdrawal was handled is [uncertain].

3. How it caused harm

  • Hypernatraemia and electrolyte disturbance. Hypernatraemia was a known, common side effect, listed in one consent form at a 21% risk [source: Science-Based Medicine, 2013]. A six-year-old boy with an inoperable brain tumour died after treatment; the final blood sodium reported to FDA was 205 mmol/L, a level critics describe as typically fatal; FDA then placed a partial clinical hold on paediatric enrolment [source: Science-Based Medicine, 2013, reporting USA Today]. NCI summaries list electrolyte imbalance among reported effects [source: NCI PDQ]. Severe hypernatraemia can cause confusion, seizures, coma and death [synthesis: general clinical knowledge].
  • Neurological toxicity. NCI lists neurological toxicity as a serious adverse effect [source: NCI PDQ]. Reporting citing NCI and consent documents states the drugs can cause coma, swelling near the brain and death, and that a 1999 NCI-linked study found side effects similar to conventional chemotherapy, including nausea, vomiting, seizures and confusion [source: Fox News, 2013].
  • Other reported effects. Fever, chills and low blood pressure after injection; flushing and fast heart rate; nausea, vomiting, abdominal pain; dizziness, headache, vertigo; muscle and joint pain and swelling; rashes; raised blood pressure, irregular beats, chest pressure; changes in platelet and white-cell counts [source: NCI PDQ]. Central venous lines carry their own infection and clotting risks [synthesis].
  • Corticosteroid exposure. High-dose steroids given alongside could produce apparent improvement on scans while exposing patients, including children, to steroid adverse effects [source: Respectful Insolence, 2013, reproducing FDA letters; synthesis for the clinical consequence].
  • Loss of effective or palliative care. Time, energy and money spent on an unproven regimen, travel and overseas relocation could displace effective treatment, approved clinical trials and timely palliative care [synthesis]. A 1992 follow-up of four patients featured on television in 1988 found two had died and one had recurred [source: Fox News, 2013].
  • Financial harm. Up-front payments, monthly charges, families spending reportedly hundreds of thousands of dollars, and public fundraising campaigns in the UK and elsewhere [source: Fox News, 2013; Science-Based Medicine, 2013; BMJ 2011]. Consent forms did not disclose additional costs adequately [source: FDA letters as reproduced in Respectful Insolence, 2013].
  • Corrupted information and consent. Inflated success rates, destroyed baseline scans and inconsistent records meant families decided on misleading information [source: Respectful Insolence, 2013; Fox News, 2013]. Some families were not told of the FDA investigation until journalists contacted them [source: Science-Based Medicine, 2013].
  • Psychological sequelae. Families report bewilderment after bereavement; documented reporting shows a bereaved family who had planned a foundation to help other children access the treatment later said they did not know what to think [source: Science-Based Medicine, 2013]. Complicated grief, guilt and regret, family conflict over the decision, public exposure through fundraising campaigns and testimonials, and hostility toward later medical teams are likely sequelae [synthesis].
  • Who was most at risk. Children with brain tumours (whose parents decided for them); adults with incurable cancers who had been told standard options were exhausted; overseas families reliant on public fundraising; people already distrustful of mainstream medicine [source: BMJ 2011; Science-Based Medicine, 2013; synthesis].

4. Recognising it today

Features and phrases that echo this regime (in clinic websites, crowdfunding pages, social media, documentaries or a client's account) [source: NCI PDQ; BMJ 2011; Fox News, 2013; Science-Based Medicine, 2013; synthesis for the pattern]:

  • A substance said to restore a "natural" defence or surveillance system the person with cancer is missing.
  • "Pioneering", "breakthrough" or "not available in this country" treatment requiring travel and a large sum raised publicly.
  • A "clinical trial" that the patient pays to join, with a large up-front fee and monthly charges, and a billing agreement presented after or separately from consent.
  • Many registered studies, few or none completed or published in peer-reviewed journals; success shown mainly by testimonials, scan anecdotes and promotional films.
  • "Personalised", "gene-targeted" or "targeted" combinations assembled by the same clinic, mixing an unproven agent with conventional drugs, so any response cannot be attributed.
  • A narrative of a persecuted maverick suppressed by regulators, the pharmaceutical industry or "the establishment"; legal threats against critics.
  • Responses judged by the seller, while steroids or other active drugs are given alongside.
  • Pressure to stop or decline conventional or palliative care, or discouragement from sharing records with the home oncologist [synthesis].

Red flags in a colleague's or service's practice [synthesis]:

  • Referring clients, or forwarding fundraising links, to a single overseas clinic for an unapproved cancer drug; financial or personal ties to the clinic.
  • Telling a client their oncologist is withholding a cure, or framing the alternative as the "brave" choice.
  • Treating a family's choice for a child as beyond safeguarding consideration, or not documenting it.
  • Offering "psychological preparation" for an alternative regime while discouraging coordination with treating physicians.

How legitimate options differ [synthesis unless tagged]:

  • Legitimate phase I–III trials are listed with eligibility, sponsor, ethics oversight and results; participants usually do not pay large sums for the investigational drug, and the treating oncologist can verify the trial independently [uncertain: payment rules vary by jurisdiction].
  • Approved treatments and evidence-based options are explained by the oncology team with expected benefit and harms; integrative oncology, as its professional societies describe it, is complementary to standard care, never instead of it (see entry 172).
  • Palliative care is active care focused on symptoms and quality of life and can run alongside disease-directed treatment.
  • The developer's compounds (phenylacetate-related agents) appear in the scientific literature; a laboratory or legitimate-trial mention of a related chemical does not validate the clinic regime [source: NCI PDQ for the chemistry; synthesis for the distinction].

Scoping questions to recognise it in session (illustrative): "Some families look at treatments abroad or in private clinics. Has anything like that come up for you?" · "Is the treatment you're considering part of a trial? Who runs it, and is your oncologist aware of it?" · "Has anyone asked you to pay up front or to raise money for it?"

5. What to do instead and how to help those harmed

Recommended alternatives (named). Care led by the client's oncology team; regulated clinical trials found with the oncologist through national trial registries and cancer-centre trial units; specialist palliative care alongside or after disease-directed treatment; psycho-oncology and psychological support; integrative oncology as its professional societies describe it, complementary and never instead of standard care (see entry 172) [synthesis]. The psychotherapist never performs, sells, prescribes or recommends a cancer treatment and never advises on medicines; all treatment questions route to the treating physicians [synthesis].

All interventions below are the psychotherapist's own work and are [synthesis] unless tagged; none is drawn from a published manual specific to this regime.

5.1 Asking without judgement and exploring meaning

  • Purpose / when: At intake and whenever cancer, a relative's cancer, crowdfunding or overseas treatment arises; makes disclosure safe so risk can be seen.
  • Steps: (1) Ask routinely about all treatments, including private and overseas ones. (2) Record what is used or planned, who provides it, cost and whether the oncologist knows. (3) Explore the client's explanatory model: what they believe cancer is, what the treatment does, what drew them (hope, control, distrust after a bad experience, a child's life, community or online support, a film). (4) Reflect values before facts. (5) Ask permission before offering any information.
  • Example language (illustrative): "Lots of people look beyond what their hospital offers. I'm not here to judge it; I'd like to understand what this means to you." · "What would it mean for you if you didn't try it?"
  • Watch for: Defensiveness that rises when you mention the oncologist; magical certainty; secrecy from relatives or doctors; a client relaying a clinic's claims verbatim. Working: the client tells you more, including doubts.

5.2 Autonomy-respecting decision support (adults)

  • Purpose / when: An adult with capacity is weighing an unproven regime against or alongside standard care.
  • Steps: (1) Separate the decision from the relationship: their choice will not end therapy. (2) Help them list what they want from the remaining time (length, comfort, being at home, being with family, "leaving no stone unturned"). (3) Help them prepare questions for both the oncologist and the clinic: Is this an approved drug? Is the trial registered and completed? Who pays, and when? What happens if I get worse or want to stop? Will records go to my doctor? (4) Encourage a second oncological opinion if trust is broken. (5) Respect the outcome; plan for medical monitoring and an exit point either way. Do not use published decision aids unless you have reviewed them [synthesis].
  • Example language (illustrative): "It's your decision, and I'll still be here whichever way you go. Can we make sure you have the answers you'd want before you sign or pay anything?"
  • Watch for: Coercion from relatives or online groups; urgency imposed by the seller; capacity concerns (delirium, brain-tumour effects, high distress) — raise these with the medical team. Working: the client can state the trade-offs in their own words.

5.3 Coordination with treating physicians, oncology and palliative teams

  • Purpose / when: Any time an unproven regime is planned or in use, or symptoms change.
  • Steps: (1) Obtain written consent to contact the oncologist, GP or palliative team. (2) Share only what the client agrees. (3) Ask the team to explain options and to monitor the client; you do not interpret scans or laboratory results. (4) Encourage the client to keep medical follow-up and to share the clinic's records. (5) Know warning signs that need urgent medical review and say so plainly: new confusion, drowsiness, seizures, severe vomiting, fever or a problem with an intravenous line [source for the reported effects: NCI PDQ; Fox News, 2013; synthesis for the advice to seek medical review].
  • Example language (illustrative): "Would it be all right for me to let your oncologist know you're considering this, so they can keep you safe whatever you decide?" · "If you notice confusion or unusual sleepiness, that needs a doctor the same day."
  • Watch for: The client hiding the regime from the team; the team withdrawing from the client — advocate for continued palliative care. Working: one shared plan.

5.4 Children: consent, assent and safeguarding

  • Purpose / when: Parents are considering or using an unproven cancer regime for a child, or are delaying or refusing effective treatment.
  • Steps: (1) Recognise parental love and fear; parents usually act in desperation, not neglect. (2) Ensure the child's treating team knows. (3) Support age-appropriate information and the child's assent; let the child's own wishes and fears be heard separately where appropriate. (4) Where a child is being given an unapproved substance with serious risks, or deprived of effective medical care, follow local safeguarding procedures: consult your safeguarding lead, discuss with the treating team, and refer to child protection services where thresholds are met; document reasoning. (5) Keep supporting the family after any referral. Never name or describe identifiable children in fundraising or publicity contexts [synthesis].
  • Example language (illustrative): "I can see how much you want to give her every chance. Her doctors need to be part of this so that whatever happens she's kept safe and comfortable." · To a child: "Some grown-ups are deciding about your medicine. What do you want them to know?"
  • Watch for: Paediatric hypernatraemia and neurological effects were reported with this regime [source: Science-Based Medicine, 2013; NCI PDQ]; fundraising publicity exposing the child; siblings neglected. Working: the child's team is informed and involved.

5.5 Financial harm and fundraising pressure

  • Purpose / when: Up-front fees, monthly charges, loans, house sales, crowdfunding, or debts after treatment.
  • Steps: (1) Ask about money directly and without shame. (2) Help the client separate hope from the price. (3) Encourage written cost disclosure before consent, and independent financial or debt advice. (4) After the event, address shame toward donors and the community; plan what to say publicly. (5) Where costs were misrepresented, support complaints (5.10).
  • Example language (illustrative): "Before anything is paid, would it help to have every cost written down, including what happens if treatment stops early?"
  • Watch for: Billing agreements presented after consent [source: FDA letters as reproduced in Respectful Insolence, 2013]; donors pressuring the family; the client avoiding the topic. Working: decisions made with full cost information.

5.6 Supporting a client currently on the regime

  • Purpose / when: The decision is made and treatment is under way.
  • Steps: (1) Stay alongside; do not argue the decision each session. (2) Keep the medical safety net (5.3). (3) Agree in advance how the client will know if it is not working and what they would want then (palliative referral, returning to the oncologist, going home). (4) Attend to carers' exhaustion and isolation.
  • Example language (illustrative): "You've made your choice and I respect it. Can we also agree what you'd want if things don't go the way you hope?"
  • Watch for: Scan improvements credited to the regime while steroids or other drugs are given [source: Respectful Insolence, 2013]; escalating spending; refusal of comfort care. Working: an advance plan exists.

5.7 Grief, regret and guilt after the choice

  • Purpose / when: Bereaved parents, partners or survivors who chose the regime, or relatives who opposed it.
  • Steps: (1) Assess for prolonged grief, depression, suicidality (standard risk assessment) and trauma symptoms. (2) Normalise hindsight bias: they decided with the information and hope they had, sometimes on misleading claims. (3) Use evidence-based grief interventions (e.g. structured prolonged-grief treatment) and guilt-focused cognitive work; consider moral-injury framing for betrayal by the clinic. (4) Address public exposure from fundraising or testimonials.
  • Example language (illustrative): "You chose with love and the information you were given. Some of that information wasn't true, and that isn't your fault."
  • Watch for: Self-blame, anger turned on medical staff or on the family member who disagreed, hopelessness. Working: the client can hold love and regret together.

5.8 Family conflict

  • Purpose / when: Relatives disagree about pursuing or having pursued the regime.
  • Steps: (1) Meet jointly only with consent and safety. (2) Name the shared goal (the patient's wellbeing). (3) Centre the patient's own values where they have capacity. (4) Help relatives voice fear without attacking. (5) After bereavement, address blame between relatives.
  • Example language (illustrative): "You both want the same thing for him; you've chosen different roads to it."
  • Watch for: Splitting, ultimatums, a relative cutting off contact. Working: the patient's voice is heard and disagreements are spoken rather than acted out.

5.9 Assessment and treatment after going through it

  • Purpose / when: Survivors or carers months or years later.
  • Steps: Assess grief, PTSD symptoms (medical trauma), depression, anxiety, health anxiety and mistrust of medicine (see Domain II), debt and social fallout; treat with evidence-based approaches; repair the relationship with medical care step by step, with consent and coordination.
  • Example language (illustrative): "What was the hardest part of that time? What do you need from doctors now?"
  • Watch for: Avoidance of medical follow-up; re-engagement with another unproven regime. Working: return to routine medical care.

5.10 Reporting and documentation

  • Purpose / when: Harmful adverse events, misleading advertising, misrepresented costs or credentials, or safeguarding concerns.
  • Steps: (1) Document what the client reports, dates and your actions. (2) With consent (or where law requires), support reports: in the US, the FDA (adverse events and unapproved drugs), the state medical board (for Texas, the Texas Medical Board), the state attorney general and the Federal Trade Commission for advertising; in the UK, the MHRA, the Advertising Standards Authority and Trading Standards; elsewhere the national medicines regulator and consumer authorities [uncertain: reporting route details]. (3) Follow mandatory child-protection reporting where thresholds are met. (4) Follow your own professional code on confidentiality and its limits [synthesis].
  • Example language (illustrative): "You may want regulators to know about what happened. I can help you think through whether and how to report it."
  • Watch for: Fear of legal retaliation (the clinic threatened critics with legal action [source: BMJ 2011]); suggest legal advice. Working: the client decides with full information.

5.11 Ethics and conflicts of interest

  • Purpose / when: Throughout.
  • Steps: Do not refer to, promote, sell or share fundraising for unproven cancer regimes; disclose any personal ties; stay within competence (no medical opinions); seek supervision when your own views or a client's distress strain neutrality [synthesis].
  • Example language (illustrative): "My role isn't to judge treatments; I can help you get clear answers from your medical team."
  • Watch for: Pressure to endorse; personal distress in the therapist. Working: neutral, safe, coordinated care.

Common difficulties. Client ends therapy when you suggest involving the oncologist: slow down, return to values, offer to revisit [synthesis]. Client asks you to tell them whether it works: say clearly that this is a medical question and help them put it to the oncologist, noting that regulators have not approved it [source: NCI PDQ; synthesis]. Client in late-stage illness with little time: prioritise comfort, relationships and palliative referral over debate [synthesis].

Sources

← Previous · XII-155Black salve and escharoticsNext · XII-157 →Issels' whole-body therapy